Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT05910801 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Academic and Community Cancer Research United

Collaborators